© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 90740 refers to the Hepatitis B vaccine (HepB) specifically designed for patients who are undergoing dialysis or are immunosuppressed. This vaccine is administered in a three-dose schedule via intramuscular injection. Unlike immune globulins, which offer short-term, passive immunity, vaccines like the Hepatitis B vaccine provide active, long-term immunity. This is achieved by exposing the recipient's immune system to altered forms of the hepatitis B virus, prompting the immune system to produce its own antibodies. As a result, the body retains the ability to generate these antibodies upon future exposure to the virus, thereby offering protection against hepatitis B, a chronic and potentially serious liver disease that can lead to hospitalization and even death. The vaccine is significant not only for its role in preventing hepatitis B but also for its potential to avert long-term complications associated with the disease, such as hepatocellular carcinoma, making it one of the pioneering cancer vaccines in clinical use. The Hepatitis B vaccine can be derived from the blood plasma of asymptomatic carriers or produced through recombinant technology, where a plasmid containing the hepatitis gene is inserted into baker's yeast. This yeast is then lysed, and the components are purified for use in the vaccine. It is important to note that the code 90740 specifically reports the Hepatitis B vaccine product for intramuscular use, while the actual injection procedure is reported separately. Other related codes include 90739 for adult dosage in a 2-dose or 4-dose schedule, 90743 for an adolescent 2-dose schedule, 90744 for pediatric/adolescent dosage in a 3-dose schedule, 90746 for adult 3-dose schedule dosage, and 90747 for dialysis or immunosuppressed patients in a 4-dose schedule.
© Copyright 2025 Coding Ahead. All rights reserved.
The Hepatitis B vaccine (CPT® Code 90740) is indicated for patients who are undergoing dialysis or are immunosuppressed. These patients are at a higher risk for hepatitis B infection due to their compromised immune systems, making vaccination essential for their protection against this serious liver disease.
The administration of the Hepatitis B vaccine (CPT® Code 90740) follows a structured three-dose schedule. Each dose is delivered via intramuscular injection, typically in the deltoid muscle of the upper arm. The procedure is as follows:
After the administration of the Hepatitis B vaccine, patients are typically monitored for a short period to observe for any immediate adverse reactions, such as allergic responses. It is important for healthcare providers to provide patients with information regarding potential side effects, which may include soreness at the injection site, mild fever, or fatigue. Patients should also be advised to complete the entire three-dose series to ensure optimal immunity. Follow-up appointments should be scheduled to administer the subsequent doses as per the recommended schedule. Additionally, healthcare providers may recommend serological testing to assess the patient's immune response to the vaccine, particularly in immunosuppressed individuals.
| Short Descr | HEPB VACC 3 DOSE IMMUNSUP IM | Medium Descr | HEPB VACCINE DIALYSIS/IMMUNSUP PAT 3 DOSE IM | Long Descr | Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 3 dose schedule, for intramuscular use | Related Drugs | ENGERIX-B | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Influenza, Pneumococcal Pneumonia, Hepatitis B, and Covid-19 Vaccines; Monoclonal Antibody Therapy Product | ASC Payment Indicator | Corneal tissue acquisition, hepatitis B vaccine; paid at reasonable cost. | Type of Service (TOS) | 1 - Medical Care | Berenson-Eggers TOS (BETOS) | O1G - Immunizations/Vaccinations | MUE | 1 | CCS Clinical Classification | 228 - Prophylactic vaccinations and inoculations |
| 25 | Significant, separately identifiable evaluation and management service by the same physician or other qualified health care professional on the same day of the procedure or other service: it may be necessary to indicate that on the day a procedure or service identified by a cpt code was performed, the patient's condition required a significant, separately identifiable e/m service above and beyond the other service provided or beyond the usual preoperative and postoperative care associated with the procedure that was performed. a significant, separately identifiable e/m service is defined or substantiated by documentation that satisfies the relevant criteria for the respective e/m service to be reported (see evaluation and management services guidelines for instructions on determining level of e/m service). the e/m service may be prompted by the symptom or condition for which the procedure and/or service was provided. as such, different diagnoses are not required for reporting of the e/m services on the same date. this circumstance may be reported by adding modifier 25 to the appropriate level of e/m service. note: this modifier is not used to report an e/m service that resulted in a decision to perform surgery. see modifier 57 for significant, separately identifiable non-e/m services, see modifier 59. | 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | 76 | Repeat procedure or service by same physician or other qualified health care professional: it may be necessary to indicate that a procedure or service was repeated by the same physician or other qualified health care professional subsequent to the original procedure or service. this circumstance may be reported by adding modifier 76 to the repeated procedure or service. note: this modifier should not be appended to an e/m service. | CC | Procedure code change (use 'cc' when the procedure code submitted was changed either for administrative reasons or because an incorrect code was filed) | CR | Catastrophe/disaster related | GC | This service has been performed in part by a resident under the direction of a teaching physician | GW | Service not related to the hospice patient's terminal condition |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2016-01-01 | Changed | First appearance of change in codebook. |
| 2015-07-01 | Changed | Description Changed |
| 2011-01-01 | Changed | Short description changed. |
| 2001-01-01 | Added | First appearance in code book in 2001. |
Get instant expert-level medical coding assistance.